These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9246222)

  • 21. Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action.
    Theodorou V; Chovet M; Eutamene H; Fargeau H; Dassaud M; Toulouse M; Bihoreau C; Roman FJ; Bueno L
    Gut; 2002 Oct; 51(4):522-8. PubMed ID: 12235074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1).
    Al Chawaf A; Xu K; Tan L; Vaccarino FJ; Lovejoy DA; Rotzinger S
    Peptides; 2007 Jul; 28(7):1406-15. PubMed ID: 17644218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional antagonism between nociceptin/orphanin FQ and corticotropin-releasing factor in rat anxiety-related behaviors: involvement of the serotonergic system.
    Filaferro M; Ruggieri V; Novi C; Calò G; Cifani C; Micioni Di Bonaventura MV; Sandrini M; Vitale G
    Neuropeptides; 2014 Aug; 48(4):189-97. PubMed ID: 24894718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats.
    Yang XM; Gorman AL; Dunn AJ
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1064-70. PubMed ID: 2262892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of short-term and long-term treatments with sigma ligands on the N-methyl-D-aspartate response in the CA3 region of the rat dorsal hippocampus.
    Bergeron R; de Montigny C; Debonnel G
    Br J Pharmacol; 1997 Apr; 120(7):1351-9. PubMed ID: 9105712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRF type 1 receptors of the medial amygdala modulate inhibitory avoidance responses in the elevated T-maze.
    Vicentini JE; Céspedes IC; Nascimento JO; Bittencourt JC; Viana MB
    Horm Behav; 2014 Mar; 65(3):195-202. PubMed ID: 24472740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
    Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression.
    Song C; Earley B; Leonard BE
    Brain Behav Immun; 1996 Mar; 10(1):1-16. PubMed ID: 8735565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the traditional Japanese medicine Unkei-to on the corticotropin-releasing factor-induced increase in locomotor activity.
    Terawaki K; Koike K; Yuzurihara M; Kase Y; Takeda S; Aburada M; Murakami K; Ohno S; Suzuki N; Inoue M
    Pharmacol Biochem Behav; 2004 Aug; 78(4):799-803. PubMed ID: 15301938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some of the effects of the selective sigma ligand (+)pentazocine are mediated via a naloxone-sensitive receptor.
    Couture S; Debonnel G
    Synapse; 2001 Mar; 39(4):323-31. PubMed ID: 11169783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.
    Izzo E; Sanna PP; Koob GF
    Pharmacol Biochem Behav; 2005 Aug; 81(4):701-8. PubMed ID: 16005056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic administration of CRF makes depression like changes in rats].
    Gao LC; Zou LJ; Zhang ZH; Yuan CG
    Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Apr; 42(2):95-100. PubMed ID: 19537192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-related effects of CRF and CRF-derived peptides: dissociation of behavioral, endocrine and autonomic activity.
    Diamant M; de Wied D
    Neuroendocrinology; 1993 Jun; 57(6):1071-81. PubMed ID: 8232765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of corticotropin-releasing factor receptors type 2, located in periaquaductal gray matter, in central and peripheral CRF-induced analgesic effect on somatic pain sensitivity in rats.
    Yarushkina NI; Bagaeva TR; Filaretova LP
    J Physiol Pharmacol; 2016 Aug; 67(4):595-603. PubMed ID: 27779480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in plasma corticosterone and hypothalamic CRF levels following intraventricular injection or drug-induced changes of brain biogenic amines in the rat.
    Abe K; Hiroshige T
    Neuroendocrinology; 1974; 14(3):195-211. PubMed ID: 4368483
    [No Abstract]   [Full Text] [Related]  

  • 36. Corticotropin-releasing factor in the nucleus accumbens shell induces swim depression, anxiety, and anhedonia along with changes in local dopamine/acetylcholine balance.
    Chen YW; Rada PV; Bützler BP; Leibowitz SF; Hoebel BG
    Neuroscience; 2012 Mar; 206():155-66. PubMed ID: 22245501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.
    Kupferschmidt DA; Newman AE; Boonstra R; Erb S
    Neuroscience; 2012 Mar; 204():125-33. PubMed ID: 21784132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of CRF and alpha-helical CRF(9-41) on rat fear responses, c-Fos and CRF expression, and concentration of amino acids in brain structures.
    Skórzewska A; Bidziński A; Hamed A; Lehner M; Turzyńska D; Sobolewska A; Maciejak P; Szyndler J; Wisłowska-Stanek A; Płaźnik A
    Horm Behav; 2008 Nov; 54(5):602-12. PubMed ID: 18601929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral effects of central administration of the novel CRF antagonist astressin in rats.
    Spina MG; Basso AM; Zorrilla EP; Heyser CJ; Rivier J; Vale W; Merlo-Pich E; Koob GF
    Neuropsychopharmacology; 2000 Mar; 22(3):230-9. PubMed ID: 10693150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms.
    Chae Y; Yeom M; Han JH; Park HJ; Hahm DH; Shim I; Lee HS; Lee H
    Neurosci Lett; 2008 Jan; 430(2):98-102. PubMed ID: 18060697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.